129-Men1tm1Zqw/Orl

Status

Available to order

EMMA IDEM:01386
International strain name129-Men1tm1Zqw/Orl
Alternative nameMen1+/T(argeted)91C
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolMen1tm1Zqw,
Gene/Transgene symbolMen1

Information from provider

ProviderPhilippe Bertolino
Provider affiliationLaboratoire Génétique Moléculaire, Signalisation et Cancer, CNRS, UMR5201, Universté Claude Bern
Genetic informationThe Men1 gene was disrupted by the insertion of a floxed neo/TK cassette in intron 2 and of another loxP site in intron 3. The targeted allele thus obtained is not functional in mice. No detectable Men1 transcript and protein in Men1 null mouse tissues.
Phenotypic informationThe Men1 null embryos are lethal at E11.5 to E13.5, with neural tube disclosure, and abnormalities in liver and heart development. The heterozygous Men1 mice develop hyperplastic lesions at 8 months and multiple endocrine tumours starting from 12 months.
Breeding historyThis strain is always maintained, even currently, by inbred cross (+/targeted X +/targeted), and has never been backcrossed or outcrossed.
References
  • Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs.;Bertolino Philippe, Radovanovic Ivan, Casse Huguette, Aguzzi Adriano, Wang Zhao-Qi, Zhang Chang-Xian, ;2003;Mechanisms of development;120;549-60; 12782272
  • Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1.;Bertolino Philippe, Tong Wei-Min, Galendo Dominique, Wang Zhao-Qi, Zhang Chang-Xian, ;2003;Molecular endocrinology (Baltimore, Md.);17;1880-92; 12819299

Information from EMMA

Archiving centreInstitut de Transgenose, INTRAGENE, Orléans, France

Disease and phenotype information

MGI allele-associated human disease models

Orphanet associated rare diseases, based on orthologous gene matching

MGI phenotypes (allele matching)
  • enlarged pituitary gland / MGI
  • enlarged adrenal glands / MGI
  • enlarged testis / MGI
  • increased adrenal gland tumor incidence / MGI
  • increased intestinal adenoma incidence / MGI
  • increased insulinoma incidence / MGI
  • increased glucagonoma incidence / MGI
  • increased pancreatic islet cell adenoma incidence / MGI
  • increased parathyroid adenoma incidence / MGI
  • thyroid gland hyperplasia / MGI
  • increased prolactinoma incidence / MGI
  • enlarged ovary / MGI
  • increased testis tumor incidence / MGI
  • increased ovary tumor incidence / MGI
  • increased adrenal gland adenoma incidence / MGI
  • increased pancreas tumor incidence / MGI
  • increased gonad tumor incidence / MGI
  • increased Leydig cell tumor incidence / MGI
  • increased gastrointestinal tumor incidence / MGI
  • increased gland tumor incidence / MGI
  • increased mammary gland tumor incidence / MGI
  • increased stomach tumor incidence / MGI
  • increased thyroid tumor incidence / MGI
  • increased thyroid carcinoma incidence / MGI
  • increased pancreatic islet cell carcinoma incidence / MGI
  • increased pituitary adenohypophysis tumor incidence / MGI
  • increased adrenal cortical tumor incidence / MGI
  • increased adrenocortical adenoma incidence / MGI
  • thin ventricular wall / MGI
  • trabecula carnea hypoplasia / MGI
  • delayed hepatic development / MGI
  • exencephaly / MGI
  • decreased embryo size / MGI
  • hemorrhage / MGI
  • abnormal embryonic tissue morphology / MGI
  • abnormal neural tube closure / MGI
  • thin interventricular septum / MGI
  • lethality throughout fetal growth and development, complete penetrance / MGI

Literature references

  • Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs.;Bertolino Philippe, Radovanovic Ivan, Casse Huguette, Aguzzi Adriano, Wang Zhao-Qi, Zhang Chang-Xian, ;2003;Mechanisms of development;120;549-60; 12782272
  • Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1.;Bertolino Philippe, Tong Wei-Min, Galendo Dominique, Wang Zhao-Qi, Zhang Chang-Xian, ;2003;Molecular endocrinology (Baltimore, Md.);17;1880-92; 12819299

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).